Tyra Biosciences, Inc. (TYRA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.21: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Elevated put/call ratio: 20.29; Below-average business quality.
Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or commercial revenue. The lead program, oral dabogratinib, is advancing through three concurrent Phase 2 trials in LG-UTUC, IR NMIBC, and achondroplasia in... Read more
Sell if holding. Engine safety override at $28.21: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Elevated put/call ratio: 20.29; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst cluster(9), earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-17Recent Developments — Tyra Biosciences, Inc.
Latest news
- NEWS TD Synnex To Rally More Than 8%? Here Are 10 Top Analyst Forecasts For Friday — benzinga Jun 12, 2026 positive
- NEWS Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday — benzinga Jun 11, 2026 positive
- NEWS Micron Technology To $900? Here Are 10 Top Analyst Forecasts For Wednesday — benzinga Jun 10, 2026 neutral
- NEWS B of A Securities Maintains Buy on Tyra Biosciences, Raises Price Target to $42 — benzinga Jun 10, 2026 positive
- NEWS 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga Jun 1, 2026 neutral
Generated 2026-06-17T10:01:49Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineoral dabogratinib10-K Item 1: 'Our lead program, oral dabogratinib, was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects'
- HIGHSupplierthird parties10-K Item 1A: 'We rely on third parties for the manufacture of our product candidates for preclinical and clinical development.'
Material Events(8-K, last 90d)
- 2026-04-17Item 5.02LOWTyra Biosciences board increased authorized directors from nine to ten and appointed Habib J. Dable as Class II director, term expiring at 2026 annual meeting. Dable is an advisor at RA Capital Management and former CEO of Acceleron Pharma.SEC filing →
- 2026-04-02Item 5.02LOWJulia Rueb, VP Finance, designated as principal accounting officer effective April 1, 2026, succeeding CFO Alan Fuhrman in that specific role. Fuhrman continues as principal financial officer. No CFO departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.21: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Elevated put/call ratio: 20.29; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $26.24. Score 5.6/10, moderate confidence.
Take-profit target: $44.89 (+59.1% upside). Prior stop was $26.24. Stop-loss: $26.24.
Concentration risk — Pipeline: oral dabogratinib; Concentration risk — Supplier: third parties; Quality below floor (1.2 < 4.0).
Tyra Biosciences, Inc. trades at a P/E of N/A (forward -10.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover TYRA with a consensus score of 4.3/5. Average price target: $52.
What does Tyra Biosciences, Inc. do?Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or...
Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or commercial revenue. The lead program, oral dabogratinib, is advancing through three concurrent Phase 2 trials in LG-UTUC, IR NMIBC, and achondroplasia in children. The company reported net losses of $119.9 million in 2025 and has cash expected to fund operations through at least 2027.